Related Experiment Video

Updated: Aug 7, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Long-term beta blockade: possible protection from myocardial infarction

K M Fox, M P Chopra, R W Portal

    British Medical Journal
    |January 18, 1975
    PubMed

    Insights

    Beta-blocker therapy for coronary heart disease patients admitted with prolonged chest pain did not worsen outcomes. This established beta-blockade may even protect against myocardial infarction development.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Coronary heart disease (CHD) management often involves beta-blocking drugs.
    • Patients with established CHD experiencing prolonged ischemic myocardial pain require careful clinical evaluation.

    Purpose of the Study:

    • To compare the clinical behavior and outcomes of patients with established coronary heart disease on beta-blockers versus those not on this therapy, when admitted with prolonged ischemic myocardial pain.
    • To assess if pre-existing beta-blockade influences the development of myocardial infarction or other adverse cardiac events.

    Main Methods:

    • A comparative study involving 180 patients admitted to a coronary care unit with prolonged ischemic myocardial pain.
    • Ninety patients were on established beta-blocking therapy, while 90 served as controls.
    • Clinical outcomes including transmural myocardial infarction, myocardial necrosis without infarction, and coronary insufficiency were recorded and compared.

    Main Results:

    • Fewer patients on beta-blockers developed transmural myocardial infarction (30 vs. 62).
    • A higher proportion of patients on beta-blockers were diagnosed with coronary insufficiency (40 vs. 14).
    • Incidence of sinus bradycardia, hypotension, syncope, and pulmonary edema was similar between groups.

    Conclusions:

    • Established beta-blockade does not appear to prejudice the outcome for patients with coronary heart disease admitted with prolonged ischemic myocardial pain.
    • Beta-blocker therapy may offer a protective effect, potentially reducing the incidence of myocardial infarction in this patient cohort.

    More Related Videos

    Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

    Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

    Published on: December 16, 2022

    Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

    Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

    Published on: May 26, 2023

    Related Concept Videos

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    Antihypertensive Drugs: Action of β1 Blockers01:17

    Antihypertensive Drugs: Action of β1 Blockers

    β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
    Antihypertensive Drugs: Types of β-Blockers01:28

    Antihypertensive Drugs: Types of β-Blockers

    β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...